| Molecule | Cat. No. | Product Name | 種 | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H52H7 | Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein |  Human | HEK293 | SDS-PAGE | $290.00 25ug | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H82E9 | Biotinylated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-H52E6 | Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified) | Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | ||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | HOT HLD-HP2H6 | PE-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein | Human | HEK293 | $410.00 25ug | |||
| HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) | Alexa Fluor™ 488-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer) | Human | HEK293 | SDS-PAGE | $360.00 25ug |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| VVN-001 | VVN001; VVN-001 | Phase 3 Clinical | VivaVision Biotech Inc | Dry Eye Syndromes; Xerophthalmia | 詳細 |
| P-28-R | P-28- R | Phase 1 Clinical | Canimguide Therapeutics | Head and Neck Neoplasms | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Odulimomab | Approved | Immunotech SAS | Antilfa | France | Graft vs Host Disease; Rejection of renal transplantation | null | 1997-01-01 | Rejection of renal transplantation; Graft vs Host Disease | 詳細 |
